Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $134.2 million.

  • Centessa Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1540.56% to $134.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.2 million, marking a year-over-year increase of 1540.56%. This contributed to the annual value of $114.5 million for FY2024, which is 1902.3% up from last year.
  • Centessa Pharmaceuticals' Shares Outstanding (Diluted Average) amounted to $134.2 million in Q3 2025, which was up 1540.56% from $133.7 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $134.2 million during Q3 2025, with a 5-year trough of $90.5 million in Q1 2022.
  • For the 4-year period, Centessa Pharmaceuticals' Shares Outstanding (Diluted Average) averaged around $106.4 million, with its median value being $96.6 million (2023).
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first surged by 111.96% in 2023, then soared by 3318.31% in 2025.
  • Centessa Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $93.4 million in 2022, then grew by 2.97% to $96.2 million in 2023, then rose by 19.02% to $114.5 million in 2024, then increased by 17.2% to $134.2 million in 2025.
  • Its last three reported values are $134.2 million in Q3 2025, $133.7 million for Q2 2025, and $133.0 million during Q1 2025.